https://newsmakingnews.com

CONTENTS: NOVEMBER 10, 2000

Click.  MICROSOFT & DEPARTMENT OF DEFENSE TIE-IN TO THE FLORIDA VOTE.

Click. Cancer Drug (Endostatin) Works, Without Side Effects, in Human Tests


Date: Fri, 10 Nov 2000 01:47:33 +0100
   From: "Mario Profaca" <>
Subject: FW: Possible Microsoft voting system tie-in to Florida election results

-----Original Message-----
From: State and Local Freedom of Information Issues
[]
On Behalf Of Jim Warren
Sent: Thursday, November 09, 2000 10:26 PM
To:
Subject: possible Microsoft voting system tie-in to Florida election results

[To the FOI lists, and to others by blind-cc.]

This is the final tidbit of information about Microsoft's possible connection to Florida election results.  No criticism or allegation intended; jus' the information FYI.

--jim

===
At 2:03 PM -0500 11/9/00, Gene Gaines wrote:
---
Dept of Defense reference to online vote project

See below or at:

http://www.defenselink.mil/news/Sep1999/n09131999_9909133.html

This is from 13 September 1999 Department of Defense press release stating they were looking for military volunteers to participate in the program.

I was told that the actual program conducted in Florida ultimately was larger, that it consisted of service personnel voting online from overseas, you were required to use computer with Windows 95 or 98, and that Microsoft underwrote this program.

It is my understanding the program went forward, and is being operated out of a DOD office in Roslyn, Virginia.  I know that the online voting project did go forward, that they do have a Information Systems Department, and that for a period they did have personnel in Florida working with Florida on this project.

It is my recollection that there was a press release issued from the Florida Secretary of State's office talking about the planned online voting trial in the 2000 election and its benefits.

I cannot find that page now at the Florida Secretary of State web site.

Gene Gaines


Cancer Drug (Endostatin) Works, Without Side Effects, in Human Tests

November 11, 2000

Amsterdam -- The hype surrounding the world's most talked about cancer-fighting drug gave way to the first real human test results yesterday, as researchers revealed that Endostatin has halted some advanced cancers for a while, and it seems free of the side effects that make other treatments so debilitating.

The results for the 61 cancer patients were less spectacular than Endostatin's earlier effectiveness against tumors in mice. But researchers stressed that the point of the initial human trials is to prove that the drug is safe, and, on that score, Endostatin may be the safest cancer drug ever seen.

"I'm excited. . . . I think this is the beginning of something that could really make a difference," said Dr. Paul Eber of Dana-Farber/Partners Cancer Care in Boston, one of three centers that treated a total of 61 patients in the Phase 1, or safety test, of the highly touted new drug.

Preliminary Endostatin results were leaked to the media earlier this week, but yesterday's announcement marked the first official release of the experimental data.

Endostatin is at the forefront of a whole new class of drugs that attack cancer at specific weak points, rather than poisoning cancer cells and normal cells alike the way that conventional radiation and chemotherapy treatments do. Endostatin and other "angiogenesis inhibitors" cut off the blood supply to tumors, effectively starving them.

If further testing reveals a consistent ability to hold tumors in check, Endostatin and similar drugs could do for cancer what the newer AIDS drugs such as protease inhibitors have done for that disease: allow patients to manage the condition, possibly for years.

The solid, if unsensational, results of Endostatin were reported yesterday at an international meeting on new cancer drugs held at Amsterdam's Free University. The drug, discovered in the Children's Hospital laboratory of Dr. Judah Folkman in Boston, is being developed by EntreMed, Inc. of Rockville, Md.

CLOSELY WATCHED RESULTS

Endostatin is being tested at Dana-Farber/Partners Cancer Care in Boston, at M.D. Anderson Cancer Center in Houston and at the University of Wisconsin Comprehensive Cancer Center in Madison.

Never before have the initial tests of a cancer drug been so closely watched, largely because 2 1/2 years ago, Nobel Prize-winning DNA pioneer James Watson predicted that Folkman would cure cancer in two years, based on dramatic animal tests of Endostatin and a similar drug, Angiostatin. Rumor and speculation about how patients were faring abounded during the yearlong trial in which desperately ill patients with a variety of tumors were treated with daily injections of Endostatin.

As veteran researchers expected, Endostatin didn't cure anyone or cause tumors to melt away, largely because the patients' cancers were so advanced. In fact, three patients at Dana-Farber died after they stopped taking Endostatin.

On the other hand, two of the 61 patients experienced shrinking tumors: A large tumor in the jaw of one patient in Texas shrank by more than 50 percent and became softer with Endostatin treatment, while a Boston patient's metastatic pancreatic cancer -- normally very fast-growing -- shrank by about 20 percent.

Another patient in the Texas trial, a 58-year-old man, had a virulent melanoma tumor that Endostatin halted after other therapies failed. Five of the patients, all at Dana-Farber, reached a plateau with "stable disease" -- neither growing nor shrinking -- for four months up to one year.

BLOOD SUPPLY SLOWED

Even in patients who didn't benefit, however, tests showed that the drug was slowing the blood supply to the tumor. That is exactly the way angiogenesis inhibitors are supposed to work -- destroying or blocking the network of tiny blood vessels which, Folkman proved, tumors need in order to grow and spread.

Eber said a total of 19 patients in Boston have been treated at Dana-Farber Cancer Institute, the Brigham and Women's Hospital, Beth Israel Deaconess Medical Center and Massachusetts General Hospital in the study. All have completed treatment or withdrawn from the study except for two patients. The man whose pancreatic cancer responded to the drug is still doing well but no longer taking Endostatin.

"I'm very pleased with the first-year results," Folkman told the meeting yesterday after the data were posted. He said he was particularly struck by how safe it is "and how much the patients enjoy being on it." Compared to the punishing surgery, chemotherapy and radiation that the patients had undergone in vain, the effects of Endostatin were so benign that one patient called the drug "Funstatin."